Pharmaceutical company AcelRx Pharmaceuticals Inc (Nasdaq:ACRX) stated on Wednesday its net loss of USD11.6m (USD0.23 per basic and diluted share) for its first quarter 2018 financial results.
This marks a rise in earnings when compared with net loss of USD15.6m (USD0.34 per basic and diluted share) for the first quarter of 2017.
Total revenue of USD343,000 was generated in 2018, down over total revenues of USD3.109m in 2017.
R&D and G&A expenses of USD7.5m were recorded for the quarter ended 31 March 2018, a decline from R&D and G&A expenses of USD11.1m for the prior year period, primarily due to lower Zalviso-related expenses attributed to the Phase 3 clinical program completed in 2017.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government